2025 Fellows Courses

Lunch Program: Optimizing Antiplatelet Therapy in High-Risk PCI

Sponsored by SCAI. Supported by Chiesi.
Introductory Remarks & Pre-Test Questions
Babar B Basir, DO, FSCAI, Henry Ford Health System, Detroit, MI
Case Presentation, Part 1
Adnan Khalif, M.D., FSCAI, Allegheny Health Network , Pittsburgh, PA
Pharmacodynamics of Antiplatelet Therapies
Jennifer A Rymer, MD, MBA, MHS, Duke University Hospital, Chapel Hill, NC
Poll: What Is the Primary Clinical Advantage of Cangrelor?
Babar B Basir, DO, FSCAI, Henry Ford Health System, Detroit, MI
Cangrelor in AMI & Cardiogenic Shock
Babar B Basir, DO, FSCAI, Henry Ford Health System, Detroit, MI
Optimal Antiplatelet Strategies in High-Risk Patients
Hayder D. Hashim, M.D., FSCAI, MedStar Washington Hospital Center, Washington, DC
Case Part 2 – Recap and Decision-Making
Adnan Khalif, M.D., FSCAI, Allegheny Health Network , Pittsburgh, PA
Conclusion & Post-Test Question
Babar B Basir, DO, FSCAI, Henry Ford Health System, Detroit, MI